AKTX
Akari Therapeutics Plc
$14.21
-1.27 (-8.20%)
At close · Jul 8
Going-concern doubt
— flagged May 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least a one-year period following the issuance of these condensed consolidated financial statements.”View the 10-Q filed May 19, 2026
Market Cap
$23.04M
Shares
1,750,410
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$14.21
Open$14.81
Day$13.41–15.25
52W$3.02–49.60
Avg vol 30d264K
Short int45K · 2.6% float · 1.0d
Short vol61%
DataJan 2020–Jul 2026
Filing10-Q · May 19
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−4%
below
Price vs 50-day avg
+38%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
24%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−8%
trailing
6-month return
+27%
trailing
YTD return
+23%
this year
Relative strength
+20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $15 — 200d above 50d
Institutional flow
Distributing
-71% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.58% of float · ▼ -62.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
6 holders — near 3-yr low, contrarian setup
Squeeze score
32
low risk · 0–100
Fundamentals
Revenue growth
−39%
Y/Y
Free cash flow
$-10.6M
Balance sheet
$5.2M
net cash
Quant / Vol
risk profile
Volatility
295%
annualized · 1-yr
Max drawdown
−93%
past year
ATR
15.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 19, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−4%
Neutral
Price vs 50-day avg
+38%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
24%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $10 › 200d $15 — 200d above 50d
Institutional flow
Distributing
-71% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.58% of float · ▼ -62.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
6 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $3
Now $14 · 24%
52-wk high $50
vs 200-day avg -4%
vs 50-day avg +38%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AKTX
this stock
Akari Therapeutics Plc
|
$23.04M | +22.9% | -39.5% | — | 2.6% |
|
ONC
BeOne Medicines Ltd.
|
$437.67B | -0.6% | +22179.2% | 890.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.03B | -14.0% | +20.8% | 16.3 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
6
- % held
- 3.8%
- Net QoQ
- -4.4M sh
- Top holder
- ARMISTICE CAPITAL, LLC
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AKTX | +38.7% | -8.0% | +27.3% | +38.7% | +22.9% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +38.9% | -8.8% | +19.9% | +38.9% | +13.6% |